User menu

Lack of association of the P450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients

Bibliographic reference Ragia, Georgia ; Kolovou, Vana ; Tavridou, Anna ; Elens, Laure ; Tselepis, Alexandros D. ; et. al. Lack of association of the P450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. In: Molecular Diagnosis and Therapy, Vol. 18, no. 3, p. 323-331 (2014)
Permanent URL
  1. Moghadasian Mohammed H, Mancini GB John, Frohlich Jiri J, Pharmacotherapy of hypercholesterolaemia: statins in clinical practice, 10.1517/14656566.1.4.683
  2. Superko H. Robert, Momary Kathryn M., Li Yonghong, Statins Personalized, 10.1016/j.mcna.2011.11.004
  3. Puccetti Luca, Acampa Maurizio, Auteri Alberto, Pharmacogenetics of Statins Therapy, 10.2174/157489007782418982
  4. Park J.-E., Kim K.-B., Bae S. K., Moon B.-S., Liu K.-H., Shin J.-G., Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin, 10.1080/00498250802334391
  5. Prueksaritanont Thomayant, Ma Bennett, Yu Nathan, The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6 : Simvastatin hydroxy acid metabolism is mediated by CYP3A, 10.1046/j.1365-2125.2003.01833.x
  6. Martinez-Jimenez Celia, Jover Ramiro, Teresa Donato M., Castell Jose, Jose Gomez-Lechon M., Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes, 10.2174/138920007779815986
  7. Lamba Jatinder K, Lin Yvonne S, Schuetz Erin G, Thummel Kenneth E, Genetic contribution to variable human CYP3A-mediated metabolism, 10.1016/s0169-409x(02)00066-2
  8. Klein Kathrin, Zanger Ulrich M., Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem, 10.3389/fgene.2013.00012
  9. FIEGENBAUM M, DASILVEIRA F, VANDERSAND C, VANDERSAND L, FERREIRA M, PIRES R, HUTZ M, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment, 10.1016/j.clpt.2005.08.003
  10. Kim Kyoung-Ah, Park Pil-Whan, Lee Ock-Je, Kang Dong-Kyun, Park Ji-Young, Effect of PolymorphicCYP3A5Genotype on the Single-Dose Simvastatin Pharmacokinetics in Healthy Subjects, 10.1177/0091270006295063
  11. Kivist?? Kari T, Niemi Mikko, Schaeffeler Elke, Pitk??l?? Kaisu, Tilvis Reijo, Fromm Martin F, Schwab Matthias, Eichelbaum Michel, Strandberg Timo, Lipid-lowering response to statins is affected by CYP3A5 polymorphism : , 10.1097/01.fpc.0000114762.78957.a5
  12. Willrich Maria Alice V., Hirata Mario H., Genvigir Fabiana D.V., Arazi Simone S., Rebecchi Ivanise M.M., Rodrigues Alice C., Bernik Marcia M.S., Dorea Egidio L., Bertolami Marcelo C., Faludi André A., Hirata Rosario D.C., CYP3A5⁎3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia, 10.1016/j.cca.2008.07.032
  13. Becker Matthijs L., Visser Loes E., van Schaik Ron H. N., Hofman Albert, Uitterlinden André G., Ch. Stricker Bruno H., Influence of genetic variation inCYP3A4andABCB1on dose decrease or switching during simvastatin and atorvastatin therapy, 10.1002/pds.1866
  14. Gao Yuan, Zhang Li-rong, Fu Qiang, CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin, 10.1007/s00228-008-0502-x
  15. Klein Kathrin, Thomas Maria, Winter Stefan, Nussler Andreas K., Niemi Mikko, Schwab Matthias, Zanger Ulrich M., PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo, 10.1038/clpt.2011.336
  16. Flück Christa E., Nicolo Catherine, Pandey Amit V., Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase, 10.1111/j.1472-8206.2007.00520.x
  17. Riddick D. S., Ding X., Wolf C. R., Porter T. D., Pandey A. V., Zhang Q.-Y., Gu J., Finn R. D., Ronseaux S., McLaughlin L. A., Henderson C. J., Zou L., Fluck C. E., NADPH-Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology, 10.1124/dmd.112.048991
  18. Gomes Ana M, Winter Stefan, Klein Kathrin, Turpeinen Miia, Schaeffeler Elke, Schwab Matthias, Zanger Ulrich M, Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation, 10.2217/pgs.09.7
  19. Huang N., Agrawal V., Giacomini K. M., Miller W. L., Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, 10.1073/pnas.0711621105
  20. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. .
  21. Agrawal Vishal, Choi Ji Ha, Giacomini Kathleen M., Miller Walter L., Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase : , 10.1097/fpc.0b013e32833e0cb5
  22. Elens Laure, Nieuweboer Annemieke J.M., Clarke Stephen J., Charles Kellie A., de Graan Anne-Joy M., Haufroid Vincent, van Gelder Teun, Mathijssen Ron H.J., van Schaik Ron H.N., Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin : , 10.1097/fpc.0b013e32835dc113
  23. Weir B. Disequilibrium. Genetic data analysis II. Sunderland: Sinaur Associates; 1996.
  24. NCBI dbSNP Build 137. .
  25. Oneda Beatrice, Crettol Severine, Sirot Evelyne Jaquenoud, Bochud Murielle, Ansermot Nicolas, Eap Chin B., The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test : , 10.1097/fpc.0b013e32833225e7
  26. Yang Guoping, Fu Zhimin, Chen Xiaoping, Yuan Hong, Yang Heng, Huang Yuanyuan, Ouyang Dongsheng, Tan Zhirong, Tan Hongyi, Huang Zhijun, Zhou Honghao, Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men, 10.1016/j.clinthera.2011.11.004
  27. Zhang Jing-Jing, Zhang Hua, Ding Xiao-Liang, Ma Sheng, Miao Li-Yan, Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers, 10.1007/s00228-012-1432-1
  28. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77
  29. Elens Laure, Becker Matthijs L., Haufroid Vincent, Hofman Albert, Visser Loes E., Uitterlinden André G., Stricker Bruno Ch., van Schaik Ron H.N., Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study : , 10.1097/fpc.0b013e32834c6edb
  30. Kitzmiller Joseph Paul, Sullivan Danielle M., Phelps Mitchell A., Wang Danxin, Sadee Wolfgang, CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control, 10.1515/dmdi-2012-0031
  31. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28